QUOIN PHARMACEUTICALS LT-ADR (QNRX)
US74907L3006 - ADR
Overall QNRX gets a fundamental rating of 1 out of 10. We evaluated QNRX against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of QNRX have multiple concerns. QNRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year QNRX has reported negative net income.
QNRX had a negative operating cash flow in the past year.
QNRX had negative earnings in each of the past 5 years.
In the past 5 years QNRX always reported negative operating cash flow.
1.2 Ratios
QNRX has a Return On Assets of -71.41%. This is in the lower half of the industry: QNRX underperforms 66.21% of its industry peers.
The Return On Equity of QNRX (-153.42%) is worse than 66.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.41% | ||
| ROE | -153.42% | ||
| ROIC | N/A |
ROA(3y)-122%
ROA(5y)-105.72%
ROE(3y)-1177.47%
ROE(5y)-750.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
QNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for QNRX has been reduced compared to 1 year ago.
QNRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for QNRX is higher compared to a year ago.
2.2 Solvency
QNRX has an Altman-Z score of -6.85. This is a bad value and indicates that QNRX is not financially healthy and even has some risk of bankruptcy.
QNRX has a Altman-Z score of -6.85. This is in the lower half of the industry: QNRX underperforms 70.31% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that QNRX is somewhat dependend on debt financing.
QNRX has a Debt to Equity ratio of 0.62. This is in the lower half of the industry: QNRX underperforms 74.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.85 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
QNRX has a Current Ratio of 3.15. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.15, QNRX is doing worse than 65.19% of the companies in the same industry.
QNRX has a Quick Ratio of 3.15. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
QNRX has a worse Quick ratio (3.15) than 63.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.15 | ||
| Quick Ratio | 3.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.96% over the past year.
EPS 1Y (TTM)87.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q57.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, QNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.83%
EPS Next 2Y36.95%
EPS Next 3Y25.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as QNRX's earnings are expected to grow with 25.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.95%
EPS Next 3Y25.85%
5. Dividend
5.1 Amount
No dividends for QNRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUOIN PHARMACEUTICALS LT-ADR
NASDAQ:QNRX (5/3/2024, 7:14:34 PM)
After market: 0.7923 +0.02 (+2.06%)0.7763
+0.05 (+6.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.41% | ||
| ROE | -153.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.15 | ||
| Quick Ratio | 3.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y80.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y